Galleri® in the Medicare Population.
← catalyst calendarNCT05673018 · readout ≤ 1,502 d
Sponsored by GRAIL, Inc. (industry) · GRAL — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Screening
Enrollment
50,000estimated
Sites
61
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-12 | actual | When the study began enrolling |
| Primary completion | Sep 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Intervention
- Device: Multi-Cancer Early Detection Test (Galleri®)
Primary outcome
what the primary-completion date above is the date OFIncidence rates of stage IV cancers
measured Up to 3 Years
Permalink · GRAL's whole pipeline · Catalyst calendar · Every registered study · What changed